This clinical trial evaluates the safety and efficacy of REGEND001, an autologous bronchial basal layer stem cell therapy, in patients with interstitial lung disease (ILD). The treatment involves harvesting the patient's own stem cells (expressing KRT5/P63 markers), expanding them ex vivo, and administering them via bronchoscopic infusion to regenerate damaged lung tissue.
Age 40-75 years.
Confirmed diagnosis of ILD (e.g., IPF, connective tissue disease-associated ILD).
DLCO ≥30% and <80% predicted.
Pregnancy, lactation, or plans for pregnancy within 1 year.
Active malignancy or history of malignancy.
Positive serology for HIV, HBV, HCV, or syphilis.